Treatment of Post-poliomyelitis Syndrome by Intravenous Immunoglobulin

Post-Poliomyélitis Syndrom Clinical Trial

— PPS and IGIV  

Official title:

Treatment of Post-poliomyelitis Syndrome by Intravenous Immunoglobulin: a Retrospective Study of Efficacy on Clinical and Isokinetic Criteria

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04004390
• Other study ID #: RECHMPL19_0322
• Status: Completed
• Start date: June 28, 2019
• Est. completion date: December 30, 2019

Study information

• Verified date: March 2020
• Source: University Hospital, Montpellier
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Our study evaluates the efficacy of IGIV treatment in PPS on clinical (walking and pain) and isokinetic (muscle strength) criteria, on patients with PS at Montpellier's Hospital

Description:

Patients are admitted to a multidisciplinary consultation (neurologist, PMK) to validate the indication of treatment with IGIV. Realization of a pre-therapeutic evaluation in the department of MPR on the criteria of judgment, then the patient is admitted in a service of neurology to benefit from the cure of IGIV. The patient is then re-admitted to a PMR service for post-treatment evaluation.

Collection of data retrospectively.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 17
• Est. completion date: December 30, 2019
• Est. primary completion date: December 1, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 30 Years and older

Eligibility

Inclusion Criteria:

• Diagnosis of PPS

• Pre- and post-therapeutic evaluation carried out

• Data transcribed in the computerized patient file

Exclusion Criteria:

• No walking patient

Related Conditions & MeSH terms

• Poliomyelitis
• Post-Poliomyélitis Syndrom
• Postpoliomyelitis Syndrome

Locations

Country	Name	City	State
France	Uh Montpellier	Montpellier

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital, Montpellier

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Muscular strength	Muscular strength with isokinetic	5 months
Secondary	Walking perimeter	Walking perimeter with walking test (6 minutes)	5 months